Cardiovascular risk scores do not account for the effect of treatment: A review

Heart

Volumn 97, Issue 9, 2011, Pages 689-697

  Liew, S M ^a,b   Doust, J ^c   Glasziou, P ^b,c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HEMOGLOBIN A1C; LIPID;

ADULT; AGE; AGED; ALBUMINURIA; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ETHNICITY; FAMILY HISTORY; FEMALE; GENDER; GLUCOSE INTOLERANCE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; SOCIAL STATUS; SYSTEMATIC REVIEW;

ADULT; AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79953861183     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.220442     Document Type: Review

References (44)

1. Cooper A, Nherera L, Calvert N, et al. Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London, National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008.
2. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
3. Sposito AC, Ramires JAF, Jukema JW, et al. Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. Curr Med Res Opin 2009;25:1171-8.
4. Graham IM, Stewart M, Hertog MG. Cardiovascular Round Table Task Force. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil 2006;13:839-45. (Pubitemid 44454860)
5. Montgomery AA, Fahey T, MacKintosh C, et al. Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract 2000;50:127-8. (Pubitemid 30076681)
6. Imms A, Quinn S, Nelson M. General practitioners' use of cardiovascular risk calculators. Aust Fam Physician 2010;39:57.
7. Eichler K, Zoller M, Tschudi P, et al. Barriers to apply cardiovascular prediction rules in primary care: a postal survey. BMC Fam Pract 2007;8:1.
8. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46-51.
9. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-15. (Pubitemid 34106178)
10. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. (Pubitemid 36712275)
11. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
12. Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 2010;170:27-40.
13. Piepho RW, Beal J. An overview of antihypertensive therapy in the 20th century. J Clin Pharmacol 2000;40:967-77.
14. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82.
15. Wasson JH, Sox HC, Neff RK, et al. Clinical prediction rules. applications and methodological standards. N Engl J Med 1985;313:793-9. (Pubitemid 15232315)
16. Royston P, Moons KG, Altman DG, et al. Prognosis and prognostic research: Developing a prognostic model. BMJ 2009;338:b604.
17. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
18. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. (Pubitemid 28213628)
19. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53. (Pubitemid 351640675)
20. Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 2007;37:925-32. (Pubitemid 350151189)
21. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 2003;56:880-90. (Pubitemid 37162663)
22. Mainous AG 3rd, Koopman RJ, Diaz VA, et al. A coronary heart disease risk score based on patient-reported information. Am J Cardiol. 2007;99:1236-41. (Pubitemid 46659859)
23. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82. (Pubitemid 351977019)
24. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611-19.
25. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-51, 4p following 2251.
26. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6. (Pubitemid 46180289)
27. Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation 2006;113:2897-905. (Pubitemid 44297230)
28. Wu Y, Liu X, Li X, et al. Estimation of 10-Year Risk of Fatal and Nonfatal Ischemic Cardiovascular Diseases in Chinese Adults. Circulation 2006;114:2217-25. (Pubitemid 44789496)
29. Gaziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008;371:923-31. (Pubitemid 351375276)
30. Palmieri L, Panico S, Vanuzzo D, et al. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita 2004;40:393-9. (Pubitemid 40904325)
31. 2006 World Health organization - International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Switzerland: WHO Press, World Health Organization, 2006.
32. Nissen SE. Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach? J Am Coll Cardiol 2009;54:2363-5.
33. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
34. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206. (Pubitemid 37430058)
35. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75. (Pubitemid 46360343)
36. Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment, and controlecontinued disparities in adults: United States, 2005-2006. NCHS Data Brief 2008;(3):1-8.
37. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
38. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med 1991;90:11-16.
39. Brown BG, Zhao X. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008;101:58B-62.
40. Messerli FH, Bakris GL, Ferrera RD, et al; on behalf of the AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006;8:571-83.
41. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010; 340:c2442.
42. Simes J, Voysey M, O'Connell R, et al. FIELD Study Investigators. A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One 2010;5:e8580.
43. Beswick AD, Brindle P, Fahey T, et al. A systematic review of risk scoring methods and clinical decision aids used in the primary prevention of coronary heart disease. Appendix K. Clinical Guidelines and Evidence Review for Lipid Modification. Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease, 2007; CG67. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. http://www.nice.org.uk/nicemedia/live/11982/40758/40758.pdf (accessed 16 Mar 2011).
44. Brindle P, Beswick A, Fahey T, et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752-9. (Pubitemid 44851316)